Carlyn RoseTanMD

Overview of Dr. Tan

Dr. Carlyn Rose Tan is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, Temple University Hospital - Jeanes Campus, and Memorial Sloan Kettering Monmouth. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 5 years. She is one of 96 doctors at Fox Chase Cancer Center and one of 32 doctors at Temple University Hospital - Jeanes Campus who specialize in Oncology. She has more than 20 publications and over 450 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(408) 337-2961

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2017
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2011 - 2014
Albert Einstein College of MedicineClass of 2011

Certifications & Licensure

FL State Medical License 2021 - Present
CA State Medical License 2012 - 2026
NJ State Medical License 2020 - 2025
NY State Medical License 2019 - 2025
PA State Medical License 2014 - 2024
NC State Medical License 2020 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis Start of enrollment: 2023 Mar 07
Recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Active, not recruiting
Phase 1
Roles: Principal Investigator

Publications & Presentations

PubMed

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...
Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
Journal of Clinical Oncology. 2024-12-04
Evaluating serum free light chain ratio as a biomarker in multiple myeloma.
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, Sham Mailankody, Alexander Lesokhin
Haematologica. 2024-10-03
1 citations
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
Issam S Hamadeh, Tala Shekarkhand, Colin Rueda, Ross S Firestone, Alice X Wang
Blood Advances. 2024-06-25

Abstracts/Posters

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
Carlyn Rose Tan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019